Mercato chiuso -
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
349,3 EUR | +0,90% | +3,56% | +1,69% |
Attività
Numero di dipendenti: 1 148
Vendite per attività
EUR in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Antibody-based Medicines
100,0
%
| 391 | 100,0 % | 1 134 | 100,0 % | +190,23% |
Vendite per regione
EUR in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
87,8
%
| 359 | 91,9 % | 996 | 87,8 % | +177,12% |
EMEA
5,9
%
| - | - | 67 | 5,9 % | - |
Japan
4,6
%
| 15 | 3,8 % | 52 | 4,6 % | +248,00% |
China
1,7
%
| 4 | 1,0 % | 19 | 1,7 % | +368,86% |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Founder | 52 | 01/01/08 | |
Karl Gubitz
DFI | Director of Finance/CFO | 54 | 01/06/21 |
Filip Borgions
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/15 |
Karen Massey
COO | Chief Operating Officer | 45 | 13/03/23 |
Peter Ulrichts
CTO | Chief Tech/Sci/R&D Officer | 44 | 01/01/23 |
Luc Truyen
CTO | Chief Tech/Sci/R&D Officer | 59 | 01/04/22 |
Beth Delgiacco
IRC | Investor Relations Contact | - | 01/01/18 |
General Counsel | 54 | 14/02/22 | |
Marc Schorpion
HRO | Human Resources Officer | 66 | 01/12/18 |
Arjen Lemmen
PRN | Corporate Officer/Principal | 39 | 01/01/16 |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Director/Board Member | 71 | 26/04/17 | |
Joseph deBethizy
BRD | Director/Board Member | 74 | 13/05/15 |
Pamela Klein
BRD | Director/Board Member | 63 | 28/04/16 |
Chairman | 66 | 15/10/08 | |
Founder | 52 | 01/01/08 | |
James Daly
BRD | Director/Board Member | 63 | 08/05/18 |
Steve Krognes
BRD | Director/Board Member | 56 | 27/02/23 |
Camilla Sylvest
BRD | Director/Board Member | 52 | 08/09/22 |
Ana Cespedes
BRD | Director/Board Member | 51 | 12/12/22 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 59 431 079 | 59 358 579 ( 99,88 %) | 0 | 99,88 % |
Coordinate società
Società del gruppo
Nome | Categoria e settore |
---|---|
arGEN-X BV
arGEN-X BV Pharmaceuticals: OtherHealth Technology Part of argenx SE, arGEN-X BV is a Belgian company that manufactures antibody-based medicines. The private company is based in Zwijnaarde, Belgium. |
Pharmaceuticals: Other
|
Settore
Vendite per regione
Revisioni EPS
Variaz. 1 gen. | Capi. | |
---|---|---|
+1,69% | 22,15 Mrd | |
-2,31% | 103 Mrd | |
+0,56% | 95,28 Mrd | |
-17,37% | 21,02 Mrd | |
-9,30% | 18,15 Mrd | |
-41,01% | 16,74 Mrd | |
-14,85% | 16,05 Mrd | |
+3,21% | 13,68 Mrd | |
+33,54% | 12,17 Mrd | |
-24,71% | 8,24 Mrd |
- Borsa valori
- Azioni
- Azione ARGX
- Società argenx SE